Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

被引：0
|
作者：
Chunxia Qiao
Meiyun Hu
Leiming Guo
Ming Lv
Zhou Lin
Jing Geng
Xiaoling Lang
Xinying Li
Yan Li
Yuanfang Ma
Jiannan Feng
Beifen Shen
机构：
[1] Institute of Basic Medical Sciences,Department of Immunology
[2] Henan University,Laboratory of Cellular and Molecular Immunology, Institute of Immunology
来源：
BMC Immunology | / 13卷
关键词：
TRAIL; Death receptor 5; Monoclonal antibody; Apoptosis; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Role of death receptor 5 (DR5) in apoptosis induced by anticancer agents in colon cancer cells
    Tong, Jingshan
    Yu, Jian
    Zhang, Lin
    CANCER RESEARCH, 2015, 75
  • [42] TRAIL/DR5 Signaling Promotes Macrophage Foam Cell Formation by Modulating Scavenger Receptor Expression
    Liu, Fang Fang
    Wu, Xiao
    Zhang, Yun
    Wang, Yan
    Jiang, Fan
    PLOS ONE, 2014, 9 (01):
  • [43] A novel bispecific FAP-DR5 antibody inducing potent and tumor-specific death receptor 5 (DR5) activation by fibroblast activation protein (FAP) dependent crosslinking
    Wartha, Katharina
    Weiser, Barbara
    Friess, Thomas
    Majety, Meher
    Runza, Valeria
    Herting, Frank
    Weber, Thomas
    Scheuer, Werner
    Harring, Suzana Vega
    Sade, Hadassah
    Niu, Huifeng
    CANCER RESEARCH, 2015, 75 (01)
  • [44] Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
    Wang, Y
    Engels, IH
    Knee, DA
    Nasoff, M
    Deveraux, QL
    Quon, KC
    CANCER CELL, 2004, 5 (05) : 501 - 512
  • [45] Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
    Wang, Gelin
    Wang, Xiaoming
    Yu, Hong
    Wei, Shuguang
    Williams, Noelle
    Holmes, Daniel L.
    Halfmann, Randal
    Naidoo, Jacinth
    Wang, Lai
    Li, Lin
    Chen, She
    Harran, Patrick
    Lei, Xiaoguang
    Wang, Xiaodong
    NATURE CHEMICAL BIOLOGY, 2013, 9 (02) : 84 - 89
  • [46] Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
    Wang G.
    Wang X.
    Yu H.
    Wei S.
    Williams N.
    Holmes D.L.
    Halfmann R.
    Naidoo J.
    Wang L.
    Li L.
    Chen S.
    Harran P.
    Lei X.
    Wang X.
    Nature Chemical Biology, 2013, 9 (2) : 84 - 89
  • [47] A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking
    Wartha, Katharina
    Weiser, Barbara
    Friess, Thomas
    Majety, Meher
    Runza, Valeria
    Herting, Frank
    Weber, Thomas
    Scheuer, Werner
    Harring, Suzana Vega
    Sade, Hadassah
    Niu, Huifeng
    Bruenker, Peter
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
    El-Gazzar, Ahmed
    Perco, Paul
    Eckelhart, Eva
    Anees, Mariam
    Sexl, Veronika
    Mayer, Bernd
    Liu, Yanxin
    Mikulits, Wolfgang
    Horvat, Reinhard
    Pangerl, Thomas
    Zheng, Dexian
    Krainer, Michael
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (04) : 1007 - 1018
  • [49] Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation
    Juthathip Mongkolsapaya
    Jonathan M. Grimes
    Nan Chen
    Xiao-Ning Xu
    David I. Stuart
    E.Yvonne Jones
    Gavin R. Screaton
    Nature Structural Biology, 1999, 6 : 1048 - 1053
  • [50] HuR regulates death receptor-5 (DR5, TRAIL-R2)-targeted treatment of pancreatic cancer cells
    Rittenhouse, David W.
    Valley, Christopher
    Cozzitorto, Joseph A.
    Richards, Nathan G.
    Talbott, Vanessa A.
    Yeo, Charles J.
    Sachs, Jonathan N.
    Witkiewicz, Agnieszka K.
    Brody, Jonathan R.
    CANCER RESEARCH, 2011, 71
12345